Shane Olwill Joins Asgard Therapeutics to Lead Cancer Immunotherapy Breakthrough

Lund, Sweden – March 26, 2025 – Asgard Therapeutics, a biotech company pushing the boundaries of cancer treatment, has welcomed Shane Olwill, PhD, as its new Chief Development Officer (CDO). With a track record of successfully advancing multiple clinical programs, Olwill will oversee the transition of Asgard’s lead therapy, AT-108, into human trials. AT-108 is an innovative cell reprogramming therapy that forces tumors to expose their own antigens, allowing the immune system to launch a personalized attack against cancer. Following a major proof-of-concept study published in Science, Olwill’s leadership marks a key step toward bringing this potential game-changer to patients.

With over a decade in immuno-oncology, Olwill previously played a crucial role in developing new therapies at Pieris Pharmaceuticals and Fusion Antibodies. Holding over 60 intellectual property rights, he is a well-respected expert in the field. Asgard’s CEO expressed excitement about his arrival, emphasizing his ability to bridge scientific discovery with real-world patient impact. “Shane’s expertise will help us turn groundbreaking research into a tangible solution for cancer patients worldwide,” the CEO stated.